Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
10Customers
1Debt Items
0Related Chains
Source-Backed Evidence Depth
Senti Biosciences Holdings, Inc. (SNTI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
4Distinct source URLs
8High confidence
0.781Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Senti Biosciences Holdings, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CELADON-PARTNERS-SPV-24
CELADON-PARTNERS-SPV-24
92%
The Investor is an entity affiliated with Celadon Partners SPV 24
GENEFAB-LLC
GENEFAB-LLC
92%
The Company currently depends on GeneFab LLC (“GeneFab”) as its sole contract manufacturer for the clinical-scale production of its product candidates.
Senti Biosciences Holdings, Inc. Customers
Ticker
Name
Confidence
Evidence
GENEFAB
GENEFAB
92%
The Letter Agreement provides, among other things, that the outstanding base rent of $1,374,005 owed by GeneFab to the Company may be satisfied, in whole or in part, through a cash prepayment credit …
BLUEROCK-THERAPEUTICS-LP
BLUEROCK-THERAPEUTICS-LP
90%
In May 2021, we entered into a Collaboration and Option Agreement with BlueRock Therapeutics LP.
CELEST-THERAPEUTICS
CELEST-THERAPEUTICS
90%
If Celest Therapeutics exercises its option during the option exercise period, the parties shall negotiate the terms of the license agreement, which will include and be consistent with pre-agreed fin…
SPARK-THERAPEUTICS
SPARK-THERAPEUTICS
85%
Pursuant to the Spark Agreement, we received an upfront payment from Spark Therapeutics of $3 million.
CHARDAN-CAPITAL-MARKETS-LLC
CHARDAN-CAPITAL-MARKETS-LLC
62%
Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) — Note 5 — Operating Leases ” in this Report for details. Interest in…
JLSA2-THERAPEUTICS-INC
JLSA2-THERAPEUTICS-INC
62%
ease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years . On March 17, 2026, the Company and the Alameda Landlord ent…
LEERINK-PARTNERS
LEERINK-PARTNERS
62%
Item 8. “Consolidated Financial Statements —Notes to Consolidated Financial Statements — Note 5 — Operating Leases” in this Annual Report for details. Change in fair value of GeneFab Note Receivable …
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
ease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years . On March 17, 2026, the Company and the Alameda Landlord ent…
SENTI-HOLDINGS
SENTI-HOLDINGS
62%
enior secured convertible notes in up to two tranches, subject to specified closing conditions. The initial tranche consists of $10.0 million, with an additional tranche of up to $30.0 million subjec…
SOUTH-LOOP-OWNER-LLC
SOUTH-LOOP-OWNER-LLC
62%
and prospects. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay f…
Senti Biosciences Holdings, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SNTI-DEBT-12651
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Senti Biosciences Holdings, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Senti Biosciences Holdings, Inc..
Senti Biosciences Holdings, Inc. Ownership
Holder
Name
Confidence
Evidence
SNTI-OWNER-NEA-MANAGEMENT-COMPANY-LLC
NEA Management Company, LLC
90%
13F overlay lists NEA Management Company, LLC as top holder; 16 tracked holders.
Senti Biosciences Holdings, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
Senti Biosciences Holdings, Inc. Supply Chain Intel
